Evidence map›Paper›PMID 31631236›Full record

ArticleInflammation2020

Effect of (-)-α-Bisabolol on the Inflammatory Response in Systemic Infection Experimental Model in C57BL/6 Mice.

Heitor Augusto Otaviano Cavalcante, Saulo Euclides Silva-Filho, Luiz Alexandre Marques Wiirzler, Gabriel Fernando Esteves Cardia, Nancy Sayuri Uchida, Francielli Maria de Souza Silva-Comar, Ciomar Aparecida Bersani-Amado, Roberto Kenji Nakamura Cuman

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Effect of Ylang-Ylang (Molecules (Basel, Switzerland) · 2022
    Article
  8. Review
  9. PPAR research · 2022
    Article
  10. Review
  11. Ethanolic Extract ofNutrients · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Heitor Augusto Otaviano CavalcanteDepartment of Pharmacology and Therapeutics, State University of Maringá, Maringá, PR, Brazil.
Saulo Euclides Silva-FilhoPharmaceutical Sciences, Food and Nutrition College, Federal University of Mato Grosso do Sul, Av. Costa e Silva, s/n, Campo Grande, MS, 79070-900, Brazil. saulo.esf@gmail.com.ORCID http://orcid.org/0000-0002-9676-7622
Luiz Alexandre Marques WiirzlerHealth Sciences School, Federal University of Grande Dourados, Dourados, MS, Brazil.
Gabriel Fernando Esteves CardiaDepartment of Pharmacology and Therapeutics, State University of Maringá, Maringá, PR, Brazil.
Nancy Sayuri UchidaDepartment of Pharmacology and Therapeutics, State University of Maringá, Maringá, PR, Brazil.
Francielli Maria de Souza Silva-ComarDepartment of Pharmacology and Therapeutics, State University of Maringá, Maringá, PR, Brazil.
Ciomar Aparecida Bersani-AmadoDepartment of Pharmacology and Therapeutics, State University of Maringá, Maringá, PR, Brazil.
Roberto Kenji Nakamura CumanDepartment of Pharmacology and Therapeutics, State University of Maringá, Maringá, PR, Brazil.
Universidade Estadual de Maringá · BRUniversidade Federal da Grande Dourados · BRUniversidade Federal de Mato Grosso do Sul · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(-)-α-Bisabolol (BISA) is an unsaturated monocyclic sesquiterpenes compound, mainly found in the essential oil of chamomile (Matricaria chamomilla). It has been reported that this compound has several biological activities, but there are few studies evaluating the activity of this compound in the systemic inflammatory response in infectious processes. The aim of this study was to evaluate the effect of BISA on the inflammatory response and survival rate in a systemic infection model, and in vitro neutrophils phagocytic activity. BISA at concentration of 3, 10, 30, and 90 μg/ml did not presented in vitro cytotoxicity in MTT assay, and at concentrations of 1 and 3 μg/ml the BISA treatment increased in vitro phagocytic neutrophil activity. For the inflammatory response study, we verified the BISA treatment effect in a cecal ligation and puncture (CLP)-induced systemic infection model in mice; in this model, we demonstrate that BISA at dose of 100 mg/kg reduced the leukocyte recruitment in peritoneal cavity; at dose of 200 mg/kg, the NO concentration was increased in the peritoneal cavity. The bacteria CFU number was reduced in mice blood in the BISA treatment, at doses of 100 and 200 mg/kg. The BISA treatment at doses of 50 and 100 mg/kg increased the myeloperoxidase activity and reduction NO production in lung tissue of mice in CLP model. At dose of 100 mg/kg, the BISA treatment was able to reduce the mortality rate of mice submitted to CLP-induced sepsis and observed for 7 days. The results suggest an effect of BISA on inflammatory response, with activity on leukocyte chemotactic and NO production, in addition to increasing the survival rate of animals submitted to CLP model.

Indexed as

AnimalsAnti-Inflammatory AgentsBacterial LoadCells, CulturedChemotaxis, LeukocyteDisease Models, AnimalFemaleHost-Pathogen InteractionsInflammationLungMice, Inbred C57BLMonocyclic SesquiterpenesNeutrophilsNitric OxidePeritoneumPhagocytosisAnti-Inflammatory AgentsbisabololMonocyclic SesquiterpenesNitric Oxideinflammationnatural productssystemic infection(-)-α-bisabolol

Identifiers

PMID31631236
OpenAlexW2980588811

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.